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Abstract
Background: Blood fluidity is maintained by a delicate balance between
coagulation and fibrinolysis. The endothelial cell surface is a key player in this
equilibrium and cell surface disruptions can upset the balance. We investigated
the role of pericellular myeloperoxidase oxidized LDLs (Mox-LDLs) in this
balance. Methods and Results: We designed a technical device that enabled
us to monitor fibrinolysis in real-time at the surface of an endothelial cell line
(EA.hy926), and showed that Mox-LDL decreased pericellular fibrinolysis. There
were no changes in fibrinolysis when EA.hy926 endothelial cells were exposed
to native LDL (24 hours) at doses of 10, 50, 100 and up to 1250 μg/ml.
However, treatment of EA.hy926 endothelial cells with 10 and 50 μg/ml of Mox-
LDL (physiological serum concentrations) increased the lysis time by 15 and
13%, respectively (p&lt;0.001), although this effect was not present at higher
concentrations of 100 μg/ml. This effect was not correlated with any ch...
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Abstract
Background: Blood fluidity is maintained by a delicate balance between coagulation and fibrinolysis. The endothelial cell
surface is a key player in this equilibrium and cell surface disruptions can upset the balance. We investigated the role of
pericellular myeloperoxidase oxidized LDLs (Mox-LDLs) in this balance.
Methods and Results: We designed a technical device that enabled us to monitor fibrinolysis in real-time at the surface of
an endothelial cell line (EA.hy926), and showed that Mox-LDL decreased pericellular fibrinolysis. There were no changes in
fibrinolysis when EA.hy926 endothelial cells were exposed to native LDL (24 hours) at doses of 10, 50, 100 and up to
1250 mg/ml. However, treatment of EA.hy926 endothelial cells with 10 and 50 mg/ml of Mox-LDL (physiological serum
concentrations) increased the lysis time by 15 and 13%, respectively (p,0.001), although this effect was not present at
higher concentrations of 100 mg/ml. This effect was not correlated with any changes in PAI-1 or t-PA or PA Receptor (PAR)
expression. No effect was observed at the surface of smooth muscle cells used as controls.
Conclusion: Our data link the current favorite hypothesis that modified LDL has a causal role in atheroma plaque formation
with an old suggestion that fibrin may also play a causal role. Our data help complete the paradigm of atherosclerosis:
Modified LDL locally enhances fibrin deposition (present work); fibrin deposits enhance endothelial permeability; this effect
allows subendothelial accumulation of lipid and foam cells.
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Introduction
Atherosclerosis is a clinical condition for which multiple genetic
and environmental causal factors have been proposed. The
atherosclerotic process involves thickening of the arterial wall;
this thickening is related to the accumulation of foam cells,
macrophages that have engulfed large amounts of modified LDL
particles. These macrophages differentiate from monocytes that
are recruited to the endothelium and activated to express
leukocyte adhesion molecules [1,2]. These adhesins are themselves
also induced by modified LDLs (more abundant in patients with
hypercholesterolemia), and it is, therefore, widely accepted that
they are involved in atherogenesis [3]. Observations also suggest
that myeloperoxidase (MPO), a protein secreted by activated
phagocytes, is a major physiological player in generating
modified/oxidized (lipo)proteins [4,5] via the production of
hypochlorous acid (HOCl) from H2O2 and chloride [6]. HOCl-
modified LDLs (HOCl-LDLs) are present in human atheroscle-
rotic lesions, where they are located both in vascular cells and in
extracellular spaces [4]. Clinical studies have shown that patients
with MPO-deficiency or low blood levels of MPO have reduced
risk of cardiovascular disease [5,7]. Two other studies reported
that serum MPO levels could predict prognosis in patients with
acute coronary syndromes or chest pain [8,9]. The circulating
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form of MPO can bind to LDL [10] because of its highly cationic
isoelectric point (pI .10).
Early circumstantial observations also correlated fibrin deposi-
tion with atheroma plaque formation. It has, therefore, been
proposed that a decrease in plasma or pericellular fibrinolytic
capacity may predispose to atherogenesis [11,12]. Recent clinical
studies indeed confirm a hypofibrinolytic state in atherosclerotic
patients [13].
The endothelial cell plasma membrane is a place where
coagulation and fibrinolysis are balanced in a continuous, dynamic
equilibrium. Endothelial cells themselves feed this process by
secreting coagulation and fibrinolysis factors. For example,
endothelial cells secrete at least three fibrinolysis regulators:
Tissue-plasminogen activator (t-PA), urokinase-plasminogen acti-
vator (u-PA) and plasminogen activator inhibitor-1 (PAI-1). They
also express specific receptors, which bind fibrinolysis factors (such
as u-PA, t-PA, t-PA-PAI-1 complex or plasminogen) and, thereby,
modulate their activity [14]. Therefore, any interference with the
endothelial cell surface or gene expression has possible implica-
tions for fibrinolysis and vice-versa. For example, physical forces or
clinical conditions confer a prothrombotic environment on the
endothelial membrane because they enhance fibrin generation
[15]. Conversely, fibrin deposition on confluent endothelial cells
disorganizes their regular cobblestone arrangement and increases
the monolayer permeability [16,17,18]. Fibrin also induces
endothelial cells to produce and release interleukin (IL)-8, a
leukocyte chemotactic factor [19].
Because of technical limitations, the interplay between endo-
thelial cells, oxidized LDLs and fibrinolysis has never been
properly analyzed. Using an up-to-date technical device that
allows real-time monitoring of fibrinolysis, we show a negative
effect of MPO-modified LDLs (Mox-LDLs) on pericellular
fibrinolysis. We propose a model involving increased fibrin levels
as an early event in the progression of atheroma lesions.
Results
Fibrinolytic Process at the Cell Surface
EA.hy926 endothelial cells and primary human smooth muscle
cells (SMCs) were inoculated on semiporous PET membranes
located inside cuvettes adapted to the lysis timer, and grown to
confluence. Fig. 1 shows the equipment (cuvette, membrane, ring
in metacrylate) used for cell culture and fibrinolysis recordings. An
euglobulin fraction was added to the cuvette, coagulation was
triggered by addition of thrombin, and fibrinolysis was allowed to
proceed. The course of the lysis process is shown in Fig. 2. The
lysis time calculated from the fibrinolysis curve, plotted on
Figure 3, was significantly decreased (by 30%) in the presence of
EA.hy926 endothelial cells, compared to a control, unseeded PET
membrane. In contrast, PET membrane inoculation with SMCs
did not significantly alter the lysis time (Fig. 3). To check the
integrity of the culture cells, they were analyzed by optical
microscopy before and after fibrinolysis. Fig. 4 shows that, despite
the presence of fibrin residues after the fibrinolysis assay,
EA.hy926 endothelial cells and SMCs displayed unaltered
cobblestone and spindle-shaped morphology, respectively. LDH
analysis confirmed that the cells were in good health (results not
shown).
Effects of TNF-a on the Fibrinolytic Process at the Surface
of EA.hy926 Endothelial Cells and SMCs
In a second experiment, EA.hy926 endothelial cells and SMCs
were exposed to tumor necrosis factor (TNF)-a for 24 hours prior
to washing and loading with the euglobin fraction. TNF-a is
known to have an antifibrinolytic action. Results are displayed in
Fig. 5. The profibrinolytic activity of the EA.hy926 endothelial
cells was confirmed. However, when EA.hy926 endothelial cells
were exposed to TNF-a (1 ng/ml and 10 ng/ml), a stepwise
increase in the lysis time was observed. The lack of effect of SMCs
on clot lysis time was also confirmed, even when the cells were
exposed to TNF-a. In an attempt to understand the differential
reactivity of the two cell types to TNF-a, we measured t-PA and
PAI-1 levels in the culture medium after a 24 h treatment period.
Table 1 shows that, in the medium conditioned with non-exposed
cells, the PAI-1/t-PA ratio was similar for both cell types.
Exposure to TNF-a (10 ng/ml) significantly increased the PAI-
1/t-PA ratio for both cell types, with a larger effect on SMCs.
Effect of Native LDL and Mox-LDL on the Fibrinolytic
Processes at the Surface of EA.hy926 Endothelial Cells
In a third experiment, we monitored the effects of LDL and
Mox-LDL exposure on the clot lysis time. There were no
changes in fibrinolysis when EA.hy926 endothelial cells were
exposed to native LDL (24 hours) at doses of 10, 50, 100 and
up to 1250 mg/ml, Fig. 6. However, treatment of EA.hy926
endothelial cells with 10 and 50 mg/ml of Mox-LDL increased
the lysis time by 15 and 13%, respectively, although this effect
was decreased at higher concentrations of 100 mg/ml. A final
concentration of 1250 mg/ml could not be reached in this case
because of the dilution related to MPO treatment. The effects
of Mox-LDL were very reproducible: Identical results were
obtained during the course of three independent complete
procedures involving healthy donor LDL isolation, LDL
oxidation, cell culture, healthy donor euglobulin fraction
preparation and fibrinolysis. Again, we monitored PAI-1 and
t-PA secretion subsequent to LDL and Mox-LDL treatment
and, as shown in figure 7, there was no effect (except for a
decrease of t-PA expression upon LDL treatment), in contrast to
what was observed with TNF-a treatment.
We, therefore, sought to investigate the effect of mox-LDL on
the expression of factors that have a major influence on
fibrinolysis, namely, in addition to PAI-1 and t-PA, uPAR and
annexin II, the PA receptors known to be expressed by
endothelial cells, and also plasminogen, a2-antiplasmin, a2-
macroglobulin, FXIII, FXI, FXII, and kallikrein, which are
believed to be expressed by hepatocytes, and LRP (a PAI-1/t-
PA complex receptor), expressed by macrophages [20,21]. Note
that the activity of the plasminogen receptor and another t-PA
receptor recently characterized [22,23,24] could not be tested
because the genes have not yet been identified. Thus, RNA was
extracted from EA.hy926 endothelial cells treated for 24 hours
with LDL and Mox-LDL and analyzed by qRTPCR using
appropriate primers. This experiment confirmed that plasmin-
ogen, a2-antiplasmin and a2-macroglobulin, FXIII, FXI, FXII,
kallikrein and LRP are not expressed in EA.hy926 endothelial
cells, even at basal levels (results not shown). There were no
changes observed in mRNA levels of annexin II (a t-PA
receptor [t-PAR]), LOX-1 and CL-P1 (the two scavenger
receptors previously reported to be expressed by endothelial
cells [25,26]) t-PA, PAI-1 and u-PAR.and ELISA showed that
there was no significant variation in the protein levels of PAI-1,
t-PA and the membrane or soluble forms of uPAR either.
Native LDL however slightly decreased t-PA expression.
In contrast to another pro-inflammatory stimulus, TNF-a,
which acts on PAI-1 and tPA levels, Mox-LDL at patho-
physiological concentrations did not interfere with the protein
levels (expressed by the EA.hy926 endothelial cell line) of any
known fibrinolysis factors, as recorded by ELISA.
Myeloperoxidase Modified-LDL and Fibrinolysis
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Figure 1. The experimental device. Fibrin formation and degradation occurred in adapted circular microcuvettes and were recorded by an
automated device. To monitor the effect of cells on fibrinolysis taking place at their surface, cells were inoculated on collagen coated membranes;
stuck at the bottom of glass circular micro-cuvettes; by a ring; and grown to confluence. The microcuvettes were inserted in the apparatus at 37uC,
the euglobin fraction added and clot formation started by addition of thrombin. Coagulation and fibrinolysis were then monitored by the device. In
control experiments, monitoring was performed in the presence of empty (cell-devoid) membranes or after addition of TNF-a to the cuvettes as
described.
doi:10.1371/journal.pone.0038810.g001
Figure 2. The course of the lysis process. A typical fibrinolysis monitoring. Euglobulin Clot Lysis Time (ECLT) is expressed in minutes. It is
calculated from a clot lysis primary graph; this graph records the light transmittance at 680 nm as a function of time (measured in seconds): blue
curve. Typically the transmittance decreases very quickly after thrombin addition which triggers clot formation and, after a latency time, fibrinolysis
progressively restores transmittance. The ECLT is then determined from a mathematical analysis of the recorded lysis curve. Primary and secondary
derivations of the recorded values generate the red and green graphs respectively. These graphs allow calculation of the B point, the peak to fibrin
clot lysis, and the C point, the end of the complete fibrinolysis process.
doi:10.1371/journal.pone.0038810.g002
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Discussion
Several hypotheses have been proposed to explain atheroma
plaque development, two of which involve fibrin deposition and
lipid accumulation as causal agents. Although involvement of the
latter factor has now been extensively documented, the role of
fibrin deposition has been investigated much less. To explore
whether there could be a link between these two hypotheses, we
adapted a device [27] (the lysis timer) so as to be able to monitor
fibrinolysis in real-time at the endothelial cell surface. Our
observations enable us to propose a new model integrating the
two hypotheses, in which exposure of endothelial cells to Mox-
LDLs, even at low concentrations, was associated with a reduced
capacity to eliminate the fibrin clot, thereby enhancing endothelial
permeability and foam cell accumulation.
Our data are in agreement with previous findings suggesting
that the endothelial cell membrane plays a central role in the
balance between coagulation and fibrinolysis. The normal
endothelium is known for its capacity to inhibit coagulation and
to favor fibrinolysis [28]. However, most studies performed in vitro
have monitored fibrinolysis indirectly by quantification of endo-
thelial cell production of t-PA and PAI-1. Rare attempts to
monitor fibrinolysis itself used technically complicated methods
and a system in which not all components involved in fibrinolysis
were reconstituted simultaneously [29]; the results regarding the
effects of endothelial cells on fibrinolysis were inconclusive. In
contrast, we directly monitored pericellular fibrinolysis in real-
time. We started with an euglobulin fraction containing the main
factors involved in fibrin network formation and lysis, i.e., FXIII,
fibrinogen, plasminogen, PAI-1 and t-PA; these factors were
simultaneously put into contact with EA.hy926 endothelial cells
before thrombin addition, allowing spontaneous lysis. This method
allowed us to observe a profibrinolytic effect of EA.hy926
endothelial cells that was physiologically relevant because it was
not observed with control SMCs.
Thus, despite a similar secreted PAI-1/t-PA ratio (with or
without treatment with TNF-a, an inflammatory factor known to
interfere with fibrinolysis), only EA.hy926 endothelial cells and not
SMCs had an effect on fibrin clot lysis time (in agreement with
Handt et al [29]). These observations suggest that factors other
than the two main fibrinolysis modulators could be involved. From
this point of view, the action of endothelial cells is reminiscent of
the observed profibrinolytic activity of monocytes/macrophages
[30], these two cell types share direct contact with blood in
physiological conditions and the expression of specific receptors
that are documented to enhance the fibrinolytic action of t-PA,
urokinase and plasminogen [14,24,31]. Thus, in the presence of
soluble t-PAR and t-PA bound to immobilized t-PAR, t-PA
exhibited 34- and 90-fold increases in plasminogen activation,
respectively. We, therefore, attempted as extensive a study as
possible of genes coding for PAI-1, PA and their receptors but also
other proteins involved in the control of fibrinolysis. We confirmed
that genes previously reported not to be expressed in endothelial
cells (plasminogen, a2-antiplasmin and a2-macroglobulin, LRP,
FXIII, FXII, FXI, kallikrein were not expressed in EA.hy926
endothelial cells even under basal conditions, as their mRNA was
undetectable in qRTPCR. In contrast, genes coding for annexin
II, u-PAR, PAI-1 and t-PA were expressed although not regulated
by Mox-LDL treatment. ELISA analyses of t-PA, PAI-1 and
soluble and membrane u-PAR confirmed that there was no
change at the protein level. However native LDL treatment
induced a slight but significant reduction in t-PA secretion even if
this did not come with any change in fibrinolysis. Therefore, all
our results suggest that none of the molecules well known to
regulate fibrinolysis is involved in the antifibrinolytic effect of
Mox-LDL. This is in contrast to another pro-inflammatory
stimulus, TNF-a, which we found exerted a similar action through
different factors, namely PAI-1 and t-PA. This finding raises the
question as to whether the receptor and signal transduction
pathways activated by Mox-LDL and TNF-a are different.
The TNF-a receptor and signal transduction pathways have
been well described [32], and as they were only used as a control
in order to analyze the effects of Mox-LDL in our experiments, we
believe that an extensive analysis of these pathways is beyond the
scope of this paper. However, much less information is available
on the oxLDL signal transduction pathways and none regarding
Mox-LDL. Therefore, we attempted a preliminary dissection of
Figure 3. Fibrinolytic process at the surface of endothelial cells and smooth muscle cells. A. The lysis time was compared in the presence
of EA.hy926 endothelial cells (endoth), smooth muscle cells (SMC) or without cells (control). Results are expressed as fold over control ratio (mean 6
SEM on 6 [EC and SMC] or 4 [membrane alone] independent experiments performed in triplicate). ANOVA p,0.001, *,0.05 vs control, Dunnett’s
post-hoc test.
doi:10.1371/journal.pone.0038810.g003
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the molecules involved in signal transmission after Mox-LDL
treatment.
A first experiment targeted LOX-1, the scavenger receptor that
has been reported in the literature to bind oxLDL and to mediate
its effects [33]. The results showed that neutralizing anti-LOX-1
antibodies are not able to interfere with Mox-LDL signal
transduction (as monitored by IL-8 induction) at concentrations
that inhibit oxLDL signaling (results not shown). This finding
suggests that Mox-LDL signal transduction is not mediated by
LOX-1, which was confirmed by the lack of effect of Mox-LDL on
the expression of the LOX-1 gene (results not shown) as opposed
to oxLDL that has been reported to increase LOX-1 expression
[34]. We, therefore, analyzed the expression of other putative
receptors of the scavenger family and confirmed that most
receptors of the family, namely SRB, SRD and SRF (reported
to be expressed in macrophages or non endothelial cell types), are
not expressed in endothelial cells. Of the two receptors (CL-P1 and
LOX1) reported to be expressed in endothelial cells, only LOX-1
was expressed in the EA.hy926 cell line. It is, therefore, likely that
Mox-LDL acts through an as yet unknown receptor. Finally, the
use of specific inhibitors allowed us to investigate the involvement
of the main pathways that have been reported to be involved in
oxLDL signal transduction. Thus, we co-treated cells with Mox-
LDL and either PD98059, SP600125, SB202190, GW5074,
wortmanin or calphostin C, specific inhibitors of ERK 1 and 2,
JNK, p38, Raf, IP3K and pKC, respectively. Although some of
the inhibitors demonstrated an effect on the basal level of IL-8,
none specifically interfered (neither increasing nor decreasing) with
the Mox-LDL-increased IL-8 mRNA level. This finding again
suggests that Mox-LDL elicits a signal transduction pathway
different from that triggered by Cu-oxLDL. Finally, an intriguing
observation was the effect of Mox-LDL on fibrinolysis at low but
not at higher concentrations. This result is reminiscent of previous
observations, for example the biphasic and contrasting effects on
tPA and PAI-1 secretion of different concentrations of steroid
hormones, such as 17bestradiol or progesterone [35]. Although we
Figure 4. Morphology of cells. Fibrinolysis does not affect cell health. EA.hy926 endothelial cells (panels C and D) show a cobblestone
morphology and smooth muscle cells (panels A and B) present a spindle shape, both of which are conserved after fibrinolysis (panels B and D). The
arrows in panel B indicate fibrin residues on the surface of SMCs after fibrinolysis.
doi:10.1371/journal.pone.0038810.g004
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do not have a definite explanation for this phenomenon, it may be
related to various mechanisms, including a template effect,
aggregation of the LDL particles, a negative feedback loop or
uptake of oxLDLs by 2 different receptors. That our Mox-LDL
preparations are able to enhance IL-8 production argues against a
loss of effect subsequent to aggregation. To assess the two last
hypotheses would require identification of the receptor(s).
OxLDL (Mox-LDL) plays a role in cardiovascular disease.
Another factor, impaired fibrinolytic function, was also proposed
as a main participant a long time ago. This suggestion originated
from observations by Virchow and was later supported by
circumstantial observations [36,37]. Clinical studies, always based
on plasma tPA and PAI-1 levels, have reported that the risk of
ischemic cardiovascular events is increased in patients with
impaired plasma fibrinolytic function [38,39,40]. Our observations
establish that physiological concentrations of Mox-LDL impairs
bona fide fibrinolysis at the endothelial cell surface and suggest a
different pathway than that involving TNF-a. This pathway and
the receptor triggering it remain to be identified.
In summary, our data link the current favorite hypothesis that
modified LDL has a role in atheroma plaque formation and an old
suggestion that fibrin may also play a causal role. Our data suggest
a means of completing the paradigm of atherosclerosis: Modified
LDL enhances fibrin deposition locally (current results); fibrin
deposits enhance endothelial permeability [17,18,19]; and this
effect allows subendothelial accumulation of lipid and foam cells
[41].
The mechanisms by which Mox-LDL can modify pericellular
fibrinolysis will be the subject of future investigations.
Materials and Methods
Ethics Statement
Blood sampling was approved by the CHU Charleroi hospital
ethics committee (Comite´ d’Ethique I.S.P.PC: OM008). The
studies conform to the principles outlined in the Declaration of
Helsinki. Written consent was obtained from the donors.
Cell Culture
EA.hy926, an endothelial cell line derived from the human
umbilical vein was used. This cell line results from the fusion
between HUVEC (human umbilical vein endothelial cells)
primary cells and a thioguanine resistant clone of A549 a
pulmonary adenocarcinomic human alveolar basal epithelial cell
line. EA.hy926 endothelial cells closely resemble HUVEC and
retain characteristics of differentiated endothelium such as Weibel-
Palade bodies, expression and or secretion of fibrinolysis and
Figure 5. Effects of TNF-a on the fibrinolytic process at the surface of cells. The ECLT time was compared in the absence or presence of
EA.hy926 endothelial cells (endoth) or smooth muscle cells (SMC) in culture medium supplemented with TNF-a at the indicated concentrations. Black
histograms: SMC; gray histograms: EA.hy926 endothelial cells (endoth). Results are expressed as fold over control ratio (mean 6 SEM on 4
independent experiments performed in triplicate). ANOVA ,0.001, * ,0.05 versus control, Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0038810.g005
Table 1. PAI-1 and t-PA in the culture medium after
stimulation.
Mean ± SD PAI-1 (ng/ml) t-PA (ng/ml) PAI/t-PA ratio
Endothelial cells
Control 351656 19.864.9 7.161.8
TNF (10 ng/ml) 6546225 23.964.3 11.762.8
SMCs
Control 135616 46.464.8 7.661.5
TNF (10 ng/ml) 273638 36.562.7 18.267
TNF-a triggers an anti-fibrinolytic response in endothelial cells (ECs) and
smooth muscle cells (SMCs). TNF-a was added to the culture medium of the
indicated cells at a 10 ng/ml final concentration. After 24 hours, the culture
supernatant was harvested and the total (active, latent and complexed) PAI-1
and t-PA protein concentrations were quantified by an ELISA test. Results were
expressed as PAI-1 concentration (column 1), t-PA concentration (column 2)
and PAI-1 concentration/t-PA concentration ratio (column 3) (mean 6 SEM on 3
independent experiments performed in duplicate). ANOVA ,0.001, * ,0.05 vs
control, Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0038810.t001
Myeloperoxidase Modified-LDL and Fibrinolysis
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coagulation factors, expression of cell adhesion molecules as well
as uptake modified LDL [42,43,44,45] and uptake modified LDL
[46]. Endothelial cell lines are commonly used in in vitro studies to
avoid problems associated with the use of primary culture, because
primary endothelial cells have a limited lifespan and display
characteristics that differ from batch to batch as a result of their
multidonor origin. Immortalized endothelial cell lines are gener-
ally better characterized and more stable in their endothelial traits
than endothelial cell primocultures [47]. Cells were grown in T-75
flasks with Dulbecco’s modified Eagles’ medium (DMEM)
containing 10% fetal bovine serum (FBS), 2% of a 506
concentrated HAT (1000 mM hypoxanthine, 0.4 mM aminopterin,
16 mM thymidine) solution, 1% of a 1006concentrated solution of
non essential amino acids, sodium pyruvate (1 mM) and antibi-
otics (penicillin 100 U/ml, streptomycin 100 ug/ml), all from
Lonza, Verviers, Belgium. Primary human aortic Smooth Muscle
Cells (AoSMC, Lonza) were grown in T-75 flasks with Smooth
Muscle Cell Growth Medium-2 BuletkitH (SMGM-2, Lonza).
Assessment of Pericellular Fibrinolysis
A fully computerized semi-automatic 8-channel device was
designed to measure fibrin formation and degradation in adapted
circular microcuvettes [27]. The method has been fully described
previously [27]. In brief, 40000 cells (EA.hy926 endothelial cells or
SMC) were inoculated on a polyethylene terephthalate (PET,
Whatman SA, Louvain-la-Neuve, Belgium) microporous mem-
brane (coated overnight with Type I collagen, 0.1%, Roche), in
glass circular micro-cuvettes (51 mm2, Fig. 1) and grown for 5 days
until confluence. The cells were incubated for 24 h in DMEM
medium containing the studied molecules. The medium was
discarded and the cells were washed three times with HBSS before
fibrinolytic tests. Euglobulin fractions (EF) were prepared from a
frozen plasma pool from 5 volunteers. Three hundred microliters
of acetic acid (0.25%) and 3.6 ml of desionized water were added
to 400 ml of plasma (final pH > 5.2). The samples were put into
melting ice for 20 min and centrifuged at 4000 g for 10 min at
4uC. The supernatant was discarded and the pellet was
resuspended in 400 ml of HBSS (HEPES 25 mM, pH: 7.3). This
fraction contains fibrinogen, PAI-1, t-PA, plasminogen, and to a
lesser extent alpha 2-antiplasmin and factor VIII [48]. Two
hundred and fifty microliters of EF were added in cell-seeded
cuvettes. The microcuvettes were inserted in the apparatus at
37uC. Clot formation was started by the addition of 50 ml of
thrombin (Hyphen-Biomed, reconstituted with RPMI 1640,
25 mM HEPES, 1.5 U/ml). Coagulation and fibrinolysis were
then allowed to proceed. The Euglobulin Clot Lysis Time (ECLT)
expressed in minutes (range: from 5 to 9999) was determined from
a mathematical analysis of the recorded lysis curve. As the ECLT
results in part from the balance between t-PA and PAI-1 activities,
recombinant human TNF-a (1 and 10 ng/ml) (Sigma, St Louis,
MO) was used to verify the reactivity of cells because it is known to
increase the ratio of PAI-1/t-PA secreted by the endothelium. The
cytotoxicity of the process was assessed by measuring the lactate
dehydrogenase (LDH) activity in the cell supernatant and was
always found to be ,10% of the cellular content.
Computer Fibrinolysis Analysis
The course of the lysis process is shown in Fig. 2. The x- and y-
axis represent, respectively, the time and evolution of the signal
recorded by the device. At the end of fibrinolysis, the curve is
analyzed with a mathematical algorithm. The first and second
derivatives are computed by convolution matrix. These calcula-
tions determine the peak time to clot lysis (B point, first derivative),
and the end of the complete fibrinolysis process (C point, when the
first and the second derivatives are at the background level >0).
In our experiments, the lysis time was determined by the C point
and expressed in minutes.
Figure 6. Effects of native LDL and Mox-LDL on the fibrinolytic process. Mox-LDL antagonizes the profibrinolytic effect of endothelial cells.
The clot lysis time (ECLT) in the presence of EA.hy926 endothelial cells was measured after addition of native-LDL (open circles) or Mox-LDL (solid
circles) at 10, 50, and 100 mg/ml final concentrations and compared to control conditions. Results are expressed as fold over control ratio (mean 6
SEM on 3 Mox-LDL and 3 native LDL independent experiments performed in triplicate). ANOVA ,0.001, *,0.05 vs control, Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0038810.g006
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Protein Analysis
The PAI-1, t-PA and u-PAR protein concentrations in the
medium were quantified using ELISA tests (Zymutest PAI-1
Antigen, Zymutest t-PA Antigen, u-PAR antigen Hyphen-Biomed,
France), which detect active and inactive (latent) forms of PAI-1
and t-PA, as well as t-PA/PAI-1 complexes or u-PAR respectively.
Raw data are presented as supernatant concentrations. Results are
also expressed as the ratio of PAI-1 antigen to t-PA antigen (PAI-
1/t-PA ratio).
Recombinant MPO Preparation
Recombinant MPO was prepared as described previously [49].
Each batch solution was characterized by its activity (U/ml),
protein concentration (mg/ml) and specific activity. Peroxidative
activity was determined using o-dianiside as the substrate. Protein
concentration was measured using the Lowry assay, with
ovalbumin as a standard. Each batch was checked for endotoxin
using the LONZA Kit. Concentration was always less than
100 pg/ml, which, taking into account the final dilution of the
MPO-treated LDL fraction, would contribute a final concentra-
tion of less than 0.1 pg/ml to the Mox-LDL supplemented
medium added to the cells. This concentration is 50006 less than
Figure 7. Effects of native LDL and Mox-LDL on the PAi-1 and t-PA release. MoxLDL does not interfere with PAI-1 or t-PA expression in
EA.hy926 endothelial cells. Native(nat)- or Mox (Mox)-LDL were added to the endothelial cell line EA.hy926 culture medium at final concentrations of
10, 50 and 100 mg/ml and TNF-a at 10 ng/ml. After 24 h, the culture supernatant was harvested and the total (active, latent and complexed) PAI-1
and t-PA concentrations were quantified by an ELISA test. Results are expressed as fold over control of PAI-1(panel A) and t-PA (panel B)
concentrations (mean6SEM on 6 [control native and Mox-LDL] or 4 [TNF] independent experiments performed in duplicate). ANOVA,0.001, *,0.05
vs control, Dunnett’s post-hoc test.
doi:10.1371/journal.pone.0038810.g007
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the amount shown not to have any effect on IL-8 production by
EA.hy926 cells.
Isolation of LDL and Mox-LDL Preparation
Both lipoprotein particles were isolated from plasma from sterile
blood pouches using density-gradient ultracentrifugation. The LDL
fraction (d = 1.019–1.063) was stored under nitrogen at 4uC in the
dark and oxidized according to the procedure described below: Prior
to oxidation, LDL were gel filtered (PD-10 column, Pharmacia) and
1.6 mg of LDL were oxidized by 2.1 chlorinating units of
recombinant MPO, to form the oxidized LDL (Mox-LDL) in the
presence of 1 mM H2O2 in 2 ml PBS at pH 6.5 for 5 minutes [50].
LDLs were desalted again after MPO treatment. Protein concentra-
tionwasmeasuredbytheLowryassay,usingovalbuminasastandard.
Statistics
SigmaStatH software (SPSS, 3.0) was used for the analysis. Data
are presented as mean 6 SEM and were evaluated by one-way
ANOVA, with Dunnett’s post-hoc test.
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